Nelson JC, Mazure CM, Jatlow PI, et al. 2004. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biol Psychiatry, 55: 296–300. Neumeister A, Young T, Stastny J. 2004. Implications of genetic research on the role of the serotonin in depression: emphasis on the serotonin type 1A receptor and the serotonin transporter. Psychopharmacology, 174:512–24. Ostroff RB, Nelson JC. 1999. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry, 60:256–9. Papakostas GI, Petersen TJ, Nierenberg AA, et al. 2004. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry, 65: 217–21. Paykel ES, Scott J, Teasdale JD, et al. 1999. Prevention of relapse in residual depression by cognitive therapy: a controlled trial. Arch Gen Psychiatry, 56:829–35. Pérez V, Puiigdemont D, Gilaberte I, et al. 2001. Augmentation of fluoxetine’s antidepressant action by pindolol: analysis of clinical, pharmacokinetic, and methodologic factors. J Clin Psychopharmacol, 21:36–45. Rabiner EA, Bhagwagar Z, Gunn RN, et al. 2001. Pindolol augmentation of selective serotonin reuptake inhibitors: PET evidence that the dose used in clinical trials is too low. Am J Psychiatry, 158:2080–2. Ramasubbu R. 2002. Treatment of resistant depression by adding noradrenergic agents to lithium augmentation of SSRIs. Ann Pharmacother, 36:634–40. Rasgon NL, Altshuler LL, Fairbanks LA, et al. 2002. Estrogen replacement therapy in the treatment of major depressive disorder in perimenopausal women. J Clin Psychiatry, 63 Suppl 7:45–8. Reynolds CF 3rd, Frank E, Perel JM, et al. 1999. Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression: a randomized controlled trial in patients older than 59 years. JAMA, 281:39–45. Rush AJ, Fava M, Wisniewski SR, et al. 2004. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials, 25:119–42. Rush A, Trivedi M. 1995. Treating depression to remission. Psychiatr Ann, 25:704–9. Sackeim HA, Haskett RF, Mulsant BH, et al. 2001. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. JAMA, 285:1299–307. Augmentation strategies in depression Serrats J, Artigas F, Mengod G, et al. 2004. An autoradiographic study of the influence of pindolol upon [35S]GTPgammaS binding in rat, guinea pig and human brain. Int J Neuropsychopharmacol, 7:27–34. Shayegan DK, Stahl SM. 2000. Buspirone. In Parnham MJ, Bruinvels J (series eds). Anxiolytics. Briley M, Nutt D (eds). Milestones in drug therapy. Basel: Birkhäuser Verlag. p 13–25. Shelton RC, Tollefson GD, Tohen M, et al. 2001. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry, 158:131–4. Shelton Clauson A, Elliott ES, Watson BD, et al. 2004. Coadministration of phenelzine and methylphenidate for treatment-resistant depression. Ann Pharmacother, 38:508. Soares CN, Cohen LS. 2001. The perimenopause, depressive disorders, and hormonal variability. Sao Paulo Med J, 119:78–83. Sokolski KN, Conney JC, Brown BJ, et al. 2004. Once-daily high-dose pindolol for SSRI-refractory depression. Psychiatry Res, 125:81–6. Stahl S. 2000. Essential psychopharmacology. Cambridge: Cambridge Univ Pr. Stewart DE, Rolfe DE, Robertson E. 2004. Depression, estrogen, and the Women’s Health Initiative. Psychosomatics, 45:445–7. Szabo ST, Blier P. 2002. Effects of serotonin (5-hydroxytryptamine, 5- HT) reuptake inhibition plus 5-HT(2A) receptor antagonism on the firing activity of norepinephrine neurons. J Pharmacol Exp Ther, 302:983–91. Tani K, Takei N, Kawai M, et al. 2004. Augmentation of milnacipran by risperidone in treatment for major depression. Int J Neuropsycho- pharmacol, 7:55–8. Thase ME. 2004. Therapeutic alternatives for difficult-to-treat depression: a narrative review of the state of the evidence. CNS Spectr, 9:808–16, 818–21. Thase ME, Greenhouse JB, Frank E, et al. 1997. Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations. Arch Gen Psychiatry, 54:1009–15. Westlund Tam L, Parry BL. 2003. Does estrogen enhance the antidepressant effects of fluoxetine? J Affect Disord, 77:87–92. Young AH, Gallagher P, Watson S, et al. 2004. Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology, 29:1538–45. Zhang W, Perry KW, Wong DT, et al. 2000. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology, 23:250–62. Neuropsychiatric Disease and Treatment 2005:1(4) 309